China, known for having one of the lowest rates of obesity in the developed world, has surprisingly emerged as one of the top locations for testing new weight loss drugs. While just 6% of the Chinese population is considered obese, compared to 31% of Australians and 40% of Americans, the country has become the second-most popular location for obesity trials in recent years.
According to a report from the clinical research organization Novotech, China is trailing only behind the U.S. in terms of hosting obesity trials, surpassing countries like Australia. Despite the seemingly low rate of obesity in China, the sheer size of the population, which stands at nearly 1.4 billion, presents a significant market for obesity drug trials and treatments. Shipra Patel, the global head of endocrinology at Parexel, a clinical research firm, highlighted that while the overall rate of obesity may not be high in China, the prevalence of overweight and obesity within the country continues to rise. This trend indicates a growing market opportunity for treating patients with obesity in China.
The rise in obesity rates within China, despite starting from a lower base compared to other countries, is a concerning trend. It suggests a shift in lifestyle and dietary habits that are contributing to the increase in overweight and obese individuals. As a result, pharmaceutical companies see China as a lucrative market for testing and launching new weight loss drugs.
However, access to the full article is restricted to STAT+ subscribers. STAT+ offers exclusive access to in-depth analysis, newsletters, premium events, and news alerts. To unlock the full content and continue reading about China’s role in obesity trials, interested readers are encouraged to subscribe to STAT+ for comprehensive coverage of the biotech and venture capital industry.
